- Stocks
- Healthcare
- NASDAQ: RVMD

Price (delayed)

$34.75

Market cap

$2.55B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.93

Enterprise value

$2.23B

The EPS has surged by 89% year-on-year and by 4% since the previous quarter

The company's equity has surged by 88% YoY and by 52% QoQ

The debt has soared by 199% YoY but it has contracted by 2.1% from the previous quarter

Revolution Medicines's net income has plunged by 121% YoY and by 16% from the previous quarter

The revenue has declined by 14% year-on-year and by 3.3% since the previous quarter

What are the main financial stats of RVMD

Market
Valuations
Earnings

Shares outstanding

73.44M

Market cap

$2.55B

Enterprise value

$2.23B

Price to earnings (P/E)

N/A

Price to book (P/B)

3.53

Price to sales (P/S)

58.87

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

53.68

Revenue

$41.57M

EBIT

-$125.45M

EBITDA

-$118.77M

Free cash flow

-$115.2M

Per share
Balance sheet
Liquidity

EPS

-$1.93

Free cash flow per share

-$1.64

Book value per share

$9.85

Revenue per share

$0.59

TBVPS

$10.46

Total assets

$811.65M

Total liabilities

$89.07M

Debt

$31.99M

Equity

$722.58M

Working capital

$653.65M

Debt to equity

0.04

Current ratio

15.94

Quick ratio

15.77

Net debt/EBITDA

2.7

Margins
Efficiency
Dividend

EBITDA margin

-285.7%

Gross margin

100%

Net margin

-302.7%

Operating margin

-305.6%

Return on assets

-20.7%

Return on equity

-24.4%

Return on invested capital

-32.8%

Return on capital employed

-16.3%

Return on sales

-301.8%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Revolution Medicines stock price performed over time

Intraday

2.18%

1 week

6.17%

1 month

8.63%

1 year

-8.62%

YTD

-12.23%

QTD

-24.26%

How have Revolution Medicines's revenue and profit performed over time

Revenue

$41.57M

Gross profit

$41.57M

Operating income

-$127.01M

Net income

-$125.82M

Gross margin

100%

Net margin

-302.7%

The net margin has plunged by 157% YoY and by 20% from the previous quarter

Revolution Medicines's operating margin has plunged by 128% YoY and by 19% from the previous quarter

Revolution Medicines's net income has plunged by 121% YoY and by 16% from the previous quarter

RVMD's operating income has dropped by 96% year-on-year and by 15% since the previous quarter

What is Revolution Medicines's growth rate over time

What is Revolution Medicines stock price valuation

P/E

N/A

P/B

3.53

P/S

58.87

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

53.68

The EPS has surged by 89% year-on-year and by 4% since the previous quarter

The company's equity has surged by 88% YoY and by 52% QoQ

The P/B is 29% lower than the last 4 quarters average of 5.0

The revenue has declined by 14% year-on-year and by 3.3% since the previous quarter

The stock's price to sales (P/S) is 8% more than its last 4 quarters average of 54.3

How efficient is Revolution Medicines business performance

The return on sales has dropped by 136% year-on-year and by 20% since the previous quarter

RVMD's ROA is down by 33% YoY but it is up by 2.8% QoQ

Revolution Medicines's return on equity has decreased by 33% YoY but it has increased by 4.7% QoQ

RVMD's ROIC is up by 13% year-on-year

What is RVMD's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for RVMD.

How did Revolution Medicines financials performed over time

RVMD's quick ratio has surged by 84% year-on-year and by 66% since the previous quarter

Revolution Medicines's current ratio has soared by 83% YoY and by 66% from the previous quarter

The debt is 96% less than the equity

The debt has soared by 199% YoY but it has contracted by 2.1% from the previous quarter

The company's equity has surged by 88% YoY and by 52% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.